Dr Kerry Gunn. Dr Nicola Broadbent. Anaesthesiologist Auckland City Hospital Auckland. Specialist Anaesthetist Auckland City Hospital Auckland

Similar documents
2010, Metzler Helfried

Evaluating the Heart before Non-Cardiac Surgery

Preoperative Cardiac Evaluation:

8/28/2018. Pre-op Evaluation for non cardiac surgery. A quick review from 2007!! Disclosures. John Steuter, MD. None

Preoperative Cardiac Risk Assessment: Approach & Guidelines

Timing of Surgery After Percutaneous Coronary Intervention

Clinical Controversies in Perioperative Medicine

GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY. Nick Collins February 2017

Preoperative Evaluation Guidelines and Work up

Assessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington

Perioperative Infarcts: Epidemiology, predictors and post-op monitoring

CV Update Guidelines & Debates Royal Pharmaceutical Society, Great Britain Barnet 27/01/09

Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center

Preoperative Risk. Geoffrey C Zarrella DO FACC. Assessment

Quality Measures MIPS CV Specific

Perioperative Cardiology Consultations for Noncardiac Surgery Ischemic Heart Disease

4/27/2015. Cardiac Events #1 cause of postoperative complications/ mortality- CHF, complete heart block, MI,

Clinical Controversies in Perioperative Medicine

The Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke

Supplementary Material to Mayer et al. A comparative cohort study on personalised

Cardiac Perioperative Risk Assessment American Heart Association Guidelines

Guidelines PATHOLOGY: FATAL PERIOPERATIVE MI NON-PMI N = 25 PMI N = 42. Prominent Dutch Cardiovascular Researcher Fired for Scientific Misconduct

North Wales Cardiac Network Guidelines on oral antiplatelet therapy in cardiovascular disease

UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES

Cardiac evaluation for the noncardiac. Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology

Perioperative Cardiac Management. Emma Sargsyan, MD, FACP

James Prentis Consultant anaesthetist. Pre-assessment and liver transplantation

DECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.

Dual Antiplatelet Therapy Made Practical

Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland

Supplementary Online Content

Post Operative Troponin Leak: David Smyth Christchurch New Zealand

Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근

SESSION 5 2:20 3:35 pm

Asian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017

Coronary Heart Disease

Value of troponin measurements in carotid artery revascularization

APPENDIX F: CASE REPORT FORM

Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University

Asif Serajian DO FACC FSCAI

Følgende dias er fremlagt ved DCS / DTS Fællesmøde 13. januar 2011 og alle rettigheder tilhører foredragsholderen. Gengivelse må kun foretages ved

TRIAL UPDATE 1. ISAR TRIPLE SECURITY Trial. Dr Deven Patel Royal Free Hospital

Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial

Primary Prevention of Stroke

Scope of the Problem: DAPT and Triple Therapy after Stenting

Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network

Manuel Castella MD PhD Hospital Clínic, University of

Best Medical Therapy for asymptomatic carotid disease

PRE Operative Care of the High Risk Surgical Patient. Dr A T Dewhurst Consultant Anaesthetist St George s Hospital London

New insights in stent thrombosis: Platelet function monitoring. Franz-Josef Neumann Herz-Zentrum Bad Krozingen

Preoperative Management of Patients Receiving Antithrombotics

TCT mdbuyline.com Clinical Trial Results Summary

Sheffield guidelines for the use of antiplatelets in the prevention and treatment of cardiovascular disease (October 2017)

Perioperative Cardiovascular Evaluation and Care for Noncardiac. Dr Mahmoud Ebrahimi Interventional cardiologist 91/9/30

Audit of perioperative management of patients with fracture neck of femur

Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά

NIH Public Access Author Manuscript Ann Vasc Surg. Author manuscript; available in PMC 2014 July 01.

Measurement Name Beta-Blocker Therapy Prior Myocardial Infarction (MI)

ACCP Cardiology PRN Journal Club

Pathology of percutaneous interventions (PCI) in coronary arteries. Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL

Downloaded from:

Learning Objectives. Epidemiology of Acute Coronary Syndrome

Consensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture

Peripheral Arterial Occlusive Disease- The Challenge in patients with diabetes

Quality Payment Program: Cardiology Specialty Measure Set

Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)

Occurrence of Bleeding and Thrombosis during Antiplatelet therapy In Non-cardiac surgery. A prospective observational study.

Cardiovascular risk reduction in diabetes Lipids (NICE CG181)

STEMI AND MULTIVESSEL CORONARY DISEASE

Medical Apps for Cardiology Uses. There s an App for That!

I have no disclosures

6/1/18 LEARNING OBJECTIVES PATIENT POPULATION PRESENTATIONS

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial

What s new in Cardiovascular medicine? Dr Stephen Dorman Consultant Cardiologist, Morriston Cardiac Centre Mid & West Cardiac Network Lead

3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.

Quality Payment Program: Cardiology Specialty Measure Set

Updates & Controversies in Perioperative Medicine

Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017

Managing Hypertension in the Perioperative Arena

D M Y Y Y Y D D M M Y Y Y Y. Previous MI (apart from acute PCI) 0=no 1=yes 9=unknown

1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES

DISCLOSURE. What I am Talking About. Rational Use of Antiplatelet Agents. Aspirin. Tom DeLoughery, MD MACP FAWM

Anesthesia for Cardiac Patients for Non Cardiac Surgery. Kimberly Westra DNP, MSN, CRNA

Controversies in Perioperative Medicine

PCI in Patients with AF Optimizing Oral Anticoagulation Regimen

Case Challenges in ACS The Very Elderly in the Cath Lab

Coronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017

ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION

Management of new-onset AF: Initial rate control treatment

Pre-op Risk Assessment. Hal Blanks MD FACC

Consensus Core Set: Cardiovascular Measures Version 1.0

Advanced Heart Failure Management. Dr Andrew Hannah Consultant Cardiologist Aberdeen Royal Infirmary

Updates & Controversies in Perioperative Medicine

Preventive Cardiology Scientific evidence

Below is summarised some of the tools and papers that are worth looking at if you have an interest in the area.

NHS Dumfries & Galloway Aspirin Discontinuation Audit May 2011 (updated August 2015)

Summary Protocol ISRCTN / NCT REVIVED-BCIS2 Summary protocol version 4, May 2015 Page 1 of 6

CPORT E Trial. Atlantic C PORT

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial

Transcription:

Dr Kerry Gunn Anaesthesiologist Auckland City Hospital Auckland Dr Nicola Broadbent Specialist Anaesthetist Auckland City Hospital Auckland 8:30-9:25 WS #96: Optimising Patients for Surgery - Defining and Reducing Risk 9:35-10:30 WS #108: Optimising Patients for Surgery - Defining and Reducing Risk (Repeated)

Optimising patients for surgery: Defining and reducing risk Nicola Broadbent Specialist Anaesthetist Auckland DHB Perioperative medicine SIG ANZCA

Topics I have selected Topics that may assist in risk discussion in the GP surgery OR That have impact on timing of elective surgery Topics Surgical risk calculator (NSQIP) Hypertension and surgery Recommended delays for elective surgery Post stroke Post MI or stent placement Perioperative aspirin

Urgency of surgery Emergency <6 hrs Urgent Time-sensitive A short delay to allow for evaluation and changes in management Usually <6 weeks Elective Minimal/restricted optimisation available Optimisation possible

Types of patients that present for surgery Patients who seek an improvement in quality of life e.g. Most elective orthopaedic operations Joint replacements Lumbar spine surgery Patients with a disease that threatens their survival Cancer surgery Vascular surgery CEA, AAA Cardiac surgery Valve surgery or coronary revascularisation

SURGICAL RISK CALCULATION

Using a surgical risk tool Risk vs benefit Can help inform the conversation YOU as the GP have the long term relationship with the patient They are likely to ask your opinion A tool Needs to be easily accessible You should have most of the information needed to complete and generate a risk estimate

Built using >1.4 million operations from hospitals participating in the National Safety and Quality Improvement Project from 2009-2012. US-centric data Uses surgical operation code and 21 patient predictors Provides estimates of 30 day mortality and complications Freely accessible online www.riskcalculator.facs.org

Example patient : Mr B Recent admission to Older Peoples Health reduced mobility and hip pain Orthopaedic surgeons reviewed him at the geriatricians request X-ray shows significant osteoarthritis of left hip They have offered him a total hip joint replacement

Background medical history 76 year old Caucasian Male Type 2 diabetic on insulin BMI 45 Wt. 122kg Ht. 165cm OSA on CPAP Chronic atrial fibrillation IHD Previous NSTEMI Cardiomyopathy with LVEF 30-35% Previous difficult to control cardiac failure On bumetanide Biventricular pacemaker for resynchronisation Treated hypertension Creatinine 169 mmol/l

On discussion Mr B claims he is miserable Can only mobilise around the house Wife assists him with bathing On oxycodone SR 20mg bd Pain wakes him at night He believes the THJR will transform his life He is willing to take any risk and appears to have lack of insight into his myriad of medical problems

Mr B and the surgical risk calculator http://riskcalculator.facs.org

HYPERTENSION AND SURGERY

Hypertension and surgery Underlying reasons for treating perioperative hypertension Long term prevention Reduce exaggerated cardiovascular responses in anaesthesia and surgery and associated morbidity Recent British guidelines published Jan 2016 Association of Anaesthetists of Great Britain and Ireland (AAGBI) & British Hypertension Society(BHS)

British consensus guidelines Undertook a review of evidence No evidence that patients with Stage 1 or 2 hypertension have increased perioperative risk Insufficient evidence in Stage 3 and 4 hypertension but potential increased risk of CVS and neurological complications No increased perioperative risk Potential CVS increased perioperative risk Patients with hypertension (controlled or uncontrolled) demonstrate a more labile haemodynamic profile than non-hypertensive counterparts Hartle et al Anaesthesia 2016. 71: 326-337.

Perioperative hypotension POISE trial Lancet 2008 Perioperative beta blockade in non cardiac surgery >8000 pt with or at risk of atherosclerotic disease Reduced risk of non fatal MI BUT Increased risk of stroke and death Linked to hypotension Due to this we may with-hold perioperative anti-hypertensives Hypotensive effect particularly pronounced with ACE inhibitors and Angiotension 2 receptor antagonists May need to be re-established after initial surgical recovery

Recommendations Take BP measured in primary care as preoperative blood pressure Clinic blood pressure may have white coat effect GP should provide recent result when referring for surgery Accept for surgery Systolic <160 mmhg Diastolic <100 mmhg Clinic blood pressure should only be taken into account If no recent primary care measurement Systolic BP >180 or diastolic >110 should be delayed for GP assessment Anti-hypertensives may be stopped for a short time perioperatively May be to be re-introduced after initial recovery in primary care

DELAYING SURGERY AFTER MEDICAL EVENTS

Stroke Recent evidence of increased risk of major cardiovascular complications for 6-9 months after a stroke Further ischaemic stroke Acute MI Cardiovascular mortality Recommend: DELAY 6-9 months for elective surgery

Danish national cohort study All patients >20 years of age undergoing non-cardiac surgery in Denmark from 2005-2011 481 183 patients of whom 7137 had suffered a prior stroke Time to surgery Odds ratio < 3 months Risk of MACE (CVS death, 14.23 MI, stroke) (11.61-17.45) 3-6 months 4.85 (3.32 7.08) 6-12 months 3.04 (2.13 4.34) >12 months 2.47 (2.07 2.95)

Major adverse cardiac events 6 months 9 months Death Ischaemic stroke Jorgensen et al. JAMA 2014

Myocardial infarction We refer to the AHA/ACC 2014 perioperative guidelines American Heart Association/American College of Cardiology Risk of perioperative MI reduces with time elapsed from MI Risk modified by coronary intervention (CABG/stent) MI <6 months also at increased risk for perioperative stroke If no coronary intervention Recommend: DELAY 60 days for elective surgery

Delay after cardiac events Stents are of most concern due to the risk of in-stent thrombosis Stopping anti-platelet drugs + pro-thrombotic risk of surgery Preference is to stop dual therapy but continue on aspirin Coronary intervention Recommended delay for elective surgery Nil but suffered MI 60 days Increased risk of stroke for 6 months Balloon angioplasty Bare metal stent Drug eluting stent 14 days 30 days 1 year Consider 6 months if risk benefit If dual anti-platelet therapy must be stopped for surgery CABG Not specified Usually 6 week stand-down

Perioperative aspirin 2 trials POISE II 2014: Aspirin and clonidine in non cardiac surgery 5000 patients at risk of vascular complications undergoing non cardiac surgery received aspirin. Low dose perioperative aspirin did not reduce risk of non fatal MI or death Increased risk of bleeding for up to 7 days ATACAS 2016: Aspirin and tranexamic acid in CABG Subgroup of 1000 patients received aspirin prior to CABG No reduction in death, thrombotic complications or non fatal MI No increased risk of bleeding

What does this mean? In NON CARDIAC surgery Aspirin does not reduce death/non fatal MI AND Aspirin may increase bleeding In CARDIAC surgery Aspirin does not reduce death/non fatal MI AND Aspirin does not increase bleeding OK to stop aspirin used for primary prevention Potential of increased bleeding with minimal benefit Risk vs benefit in secondary prevention Consider stopping aspirin for secondary prevention if distant event especially if high bleeding risk surgery Continue aspirin for secondary prevention if possible IN Coronary stents Recent MI Recent stroke

Take home messages Hypertension Primary care blood pressure should be taken as preoperative BP No evidence of increased complications for stage 1 and 2 hypertension Perioperative hypotension is bad may need to stop and re-establish anti-hypertensives Stroke Delay 6-9 months to reduce risk of mortality and major cardiac adverse events MI Delay 60 days if no coronary intervention to reduce MI risk Increased risk of stroke for 6 months Stents Continue aspirin if possible Delay 14 days for balloon angioplasty Delay 60 days for bare metal stents Delay 6-12 months for drug eluting stents if surgery cannot proceed on dual antiplatelet therapy Aspirin Stop aspirin for primary prevention Risk vs benefit in secondary prevention Open access surgical risk calculator available for risk discussion www.riskcalculator.facs.org